What do MRNA's past quarterly EPS trends reveal?

Moderna's (MRNA) past quarterly EPS trends show significant fluctuations, with substantial losses in the first quarter of 2024 and a slight positive EPS in the third quarter. Here's a detailed analysis:

1. **Significant Losses in the First Quarter**: The EPS was -$2.91 for the quarter ending December 31, 2024, and -$3.07 for the quarter ending March 31, 2025. This indicates a substantial loss during this period, which could be due to various factors such as operational losses, research and development expenses, or one-time charges.
2. **Slight Positive EPS in the Third Quarter**: In contrast, the EPS was $0.03 for the quarter ending September 30, 2024. This is a positive trend, suggesting that the company may have experienced profitability during this period.
3. **Consistent Negative EPS in the Second and Fourth Quarters**: The EPS was -$3.33 for the quarter ending June 30, 2025, which is another quarter of significant losses. This consistent trend of negative EPS in the second and fourth quarters could be indicative of ongoing challenges or expenses that the company is facing.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|MRNA|MRNA.O|Moderna|2024 Q1|-1715.7894736842102|-3.07|185|
|MRNA|MRNA.O|Moderna|2024 Q2|8.011049723756907|-3.33|185|
|MRNA|MRNA.O|Moderna|2024 Q3|100.31479538300103|0.03|185|
|MRNA|MRNA.O|Moderna|2024 Q4|-629.090909090909|-2.91|185|

In summary, Moderna's past quarterly EPS trends reveal a company that has experienced significant losses, particularly in the first and second quarters of 2025, with a slight positive EPS in the third quarter. The fourth quarter's EPS also indicates a continuation of losses, which may be a cause for concern for investors.